Highlights

  • XBiotech shares briefly moved above the 50-day moving average during Friday trading.
  • Analyst coverage remains limited, with consensus sentiment currently reflecting a sell rating.
  • Institutional investors held over half of outstanding shares following recent position changes.

Shares of XBiotech Inc. (NASDAQ:XBIT) traded above their 50-day moving average during the January 30 session, touching an intraday high of USD 2.56. The stock’s 50-day average stood at USD 2.49, while the 200-day moving average was higher at USD 2.67. Despite the intraday move, shares closed at USD 2.51, down 1.18% on the day, with trading volume reported at 9,081 shares.

Analyst Coverage — Ratings Remain Unchanged

Coverage of XBiotech by Wall Street analysts remains sparse. In late December, Weiss Ratings reaffirmed a “sell (D-)” rating on the stock. Based on aggregated data, XBiotech currently carries a consensus rating of “Sell,” reflecting limited optimism from the small group of firms actively tracking the company.

Financial Snapshot — Metrics and Earnings Context

XBiotech has a market capitalisation of approximately USD 76.53 million. The company reported a price-to-earnings ratio of -2.61 and a beta of 0.81. In its most recent quarterly update released on November 12, the company posted a loss of USD 0.20 per share, consistent with expectations for a clinical-stage biopharmaceutical firm without commercialised products.

Institutional Activity — Hedge Funds Adjust Exposure

Institutional investors accounted for about 55.70% of XBiotech’s shareholding. During the second quarter, several funds adjusted their exposure. Bank of America Corp DE increased its stake by over 40%, while BNP Paribas Financial Markets added to its existing position. Other firms, including Jane Street Group LLC and Qube Research & Technologies Ltd, reported new positions during the same period.

Business Overview — Focus on Antibody Development

XBiotech operates as a clinical-stage biopharmaceutical company developing human antibodies for cancer and inflammatory-driven diseases. Its True Human™ antibody platform is designed to produce monoclonal antibodies without genetic humanisation. The company’s lead program targets interleukin-1 alpha, a mediator linked to inflammation and tumour progression.

Latest Closing Price (as of January 30, 2026): XBiotech Inc. (NASDAQ:XBIT) closed at USD 2.51, down 1.18% on the day.